Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Wednesday

Acrivon Therapeutics (NASDAQ:ACRV) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Acrivon Therapeutics to post earnings of ($0.49) per share and revenue of $0.2770 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). On average, analysts expect Acrivon Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acrivon Therapeutics Trading Down 4.1%

Shares of ACRV opened at $2.08 on Wednesday. The company’s 50 day simple moving average is $1.64 and its 200-day simple moving average is $1.94. The firm has a market cap of $89.02 million, a PE ratio of -1.03 and a beta of 2.01. Acrivon Therapeutics has a 12-month low of $1.05 and a 12-month high of $3.56.

Hedge Funds Weigh In On Acrivon Therapeutics

Several institutional investors have recently bought and sold shares of ACRV. UBS Group AG raised its holdings in Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after purchasing an additional 682,763 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Acrivon Therapeutics by 1.7% in the 4th quarter. Renaissance Technologies LLC now owns 634,169 shares of the company’s stock valued at $1,528,000 after purchasing an additional 10,769 shares in the last quarter. Marshall Wace LLP increased its position in Acrivon Therapeutics by 231.4% during the 4th quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock worth $1,196,000 after purchasing an additional 346,366 shares during the period. Jane Street Group LLC increased its position in Acrivon Therapeutics by 18.3% during the 4th quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock worth $824,000 after purchasing an additional 52,823 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Acrivon Therapeutics by 76.2% during the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after buying an additional 138,033 shares in the last quarter. 71.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ACRV has been the subject of a number of recent research reports. Jefferies Financial Group reiterated a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Piper Sandler upped their target price on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Weiss Ratings upgraded shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, April 27th. Finally, Wall Street Zen lowered Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 1st. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.